A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
Clinical trial NCT05222802 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05222802
- Sponsor
- Katmai Pharmaceuticals Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-25
- Primary completion
- 2025-08-31
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.